Investor Presentaiton
Focus of CRL 2023 Meeting with Management
ā
-
An update on our growth drivers and strategic imperatives, as well as the
current state of the market environment
Resilience of our business model during a period of normalizing demand trends
CRL continuing to enhance capabilities around higher-growth end markets, principally
biologics and cell & gene (C>) therapies
Impact of our partnership strategy and technology
Updated financial targets through 2026
Believe we are well positioned to deliver 6%-8% organic revenue growth from 2023-26E
ESG: Our commitment to Corporate Citizenship and advancing responsible
science and the 4Rs
Technology: The digitalization of our business will transform the client
experience and our connectivity with them
Charles River Laboratories (CRL)
2View entire presentation